Print Close

Manuscript TUBI-D-15-01758R1 for review

From: **Editorial Office Tumor Biology** (em@editorialmanager.com)
Sent: Sun 7/19/15 4:34 PM
To: Shicheng Guo (shicheng.guo@hotmail.com)

Dear Dr. Guo,

In view of your expertise I would be very grateful if you could review the following manuscript which has been submitted to Tumor Biology.

Manuscript Number: TUBI-D-15-01758R1

Title: Distinct clinicopathological significances and potential drug targets of ALDH1 isoenzymes in gastric cancer

Abstract: Elevated aldehyde dehydrogenase 1 (ALDH1) activity has been determined in the stem cell populations of several kinds of tumors including gastric cancer (GC). However, which ALDH1's isoenzymes are contributing to ALDH1activity remains elusive. In this study, we examined the prognostic value and hazardous ratio (HR) of individual ALDH1 isoenzymes in GC patients through "The Kaplan-Meier plotter" (KM plotter) database. ALDH1A1 mRNA high expression was not found to be significantly correlated to overall survival (OS) for all GC patients followed for 13 years, HR 0.86 (0.7-1.05), p=0.13. ALDH1A2 mRNA high expression was also not significantly correlated to OS for all GC patients, HR 1.13 (0.91-1.41), p=0.25. ALDH1A3 mRNA high expression was found to be significantly correlated to worsen OS either in intestinal type patients, HR 2.24 (1.44-3.49), p=0.00026 or diffuse type patients, HR 1.91 (1.02-3.59), p=0.04. Interestingly, ALDH1B1 mRNA high expression was found to
be significantly correlated to better OS for all GC patients, HR 0.66 (0.53-0.81), p=7.8e-05 and ALDH1L1 mRNA high expression was found to be significantly correlated to worsen OS for all GC patients, HR 1.23 (1-1.51), p=0.048. In addition, our current study also supports that ALDH1A3 and ALDH1L1 might be major contributors to the ALDH1 activity in GC, since ALDH1A3 and ALDH1L1 mRNA high expression was found to be significantly correlated to worsen OS for all GC patients. Based on our study, ALDH1A3 and ALDH1L1 might be excellent potential drug targets for GC patients.

In case you accept to review this submission please click on this link:

http://tubi.edmgr.com/l.asp?i=233772&l=K0C158R0

If you do not have time to do this, or do not feel qualified, please click on this link:

http://tubi.edmgr.com/l.asp?i=233773&l=BBHKRSKG

We hope you are willing to review the manuscript. If so, would you be so kind as to return your review to us within 14 days of agreeing to review? Thank you.

You are requested to submit your review online by using
the Editorial Manager system which can be found at:
http://tubi.edmgr.com/. Your username is: shicheng.guo@hotmail.com and your password is: guo53465.

IN ORDER TO KEEP DELAYS TO A MINIMUM, PLEASE ACCEPT OR DECLINE THIS ASSIGNMENT ONLINE AS SOON AS POSSIBLE!

If you have any questions, please do not hesitate to contact us. We appreciate your assistance.

With kind regards,
James A. Radosevich, Ph.D.